Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617057 | 1.00 | AKR1C3 (0.38) | AKR1C3AKR1C1PDE9ANPC1ALDH1A1 | |
| SCHEMBL3660203 | 0.92 | AKR1C3 (0.33) | AKR1C3AKR1C1 | |
| SCHEMBL28386921 | 0.74 | AKR1C3 (0.41) | AKR1C3AKR1C1PDE9A | |
| SCHEMBL1616943 | 0.74 | ALDH1A1 (0.40) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1616945 | 0.74 | ALDH1A1 (0.40) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1617331 | 0.74 | STAT3 (0.31) | — | |
| SCHEMBL1616161 | 0.72 | MAPT (0.37) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1617387 | 0.71 | MAPT (0.35) | NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL1617390 | 0.71 | MAPT (0.35) | NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL30809938 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012030952-A3 | REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY | TEXAS INSTRUMENTS INCORPORATED (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2231629-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-7923450-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2231629-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009087127-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, BACE1 | AKR1C3 1824/4885AKR1C1 2167/4885PDE9A 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.